홈 카테고리 맞춤형시장조사 국제컨퍼런스 글로벌 파트너 메일링 서비스 회사소개회사소개 Contact Us
English Japaness
Home > 시장보고서 > 파머슈티컬 > Asthma Therapeutics
카테고리
파머슈티컬 (4931)
감염질환 (349)
골질환 치료 (38)
당뇨병 (194)
백신 (181)
비만치료/다이어트 (44)
비처방 의약품 (152)
수의학 (17)
신경질환 (174)
신약개발 (1529)
암치료 (941)
약물전달 (185)
의약품 규제환경 (127)
정신질환 (86)
제네릭 의약품 (128)
제약회사분석 (523)
처방약 (165)
시장보고서

Asthma Therapeutics

리서치사 Global Industry Analysts, Inc.
발행일 2006년 10월 상품코드 47290
페이지 정보 383 Pages
가격
US $ 3,950 ￦ 4,706,400 PDF by E-mail (Single User License)
US $ 3,950 ￦ 4,706,400 Hard Copy
US $ 11,850 ￦ 14,119,200 PDF By E-mail (Global License to Company and its Fully-owned Subsidiaries)

주의 : Single user license는 DRM(디지털 저작권 관리시스템) 장착 PDF로, 처음에 다운로드 받은 PC에서만 보고서 열람이 가능하며, 출력은 1부만 가능합니다. 참고로, 본 DRM파일의 다운로드 및 열람은 Adobe Digital Editions(구매 시 무료배포) 설치를 필요로 합니다. 기타 자세한 사항은 문의하여 주시기 바랍니다.

영문목차

Abstract

This report analyzes the worldwide markets for Asthma Therapeutics in US$ Million. The major therapeutic segments analyzed are Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, and Anti- leukotrienes. The report provides separate comprehensive analytics for the USA, Canada, Japan, Europe and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 70 companies including many key and niche players worldwide such as Abbott Laboratories, ALTANA Pharma AG, AstraZeneca, Boehringer Ingelheim, Genentech, Inc., GlaxoSmithKline, Merck & Co., Inc., Novartis Pharma AG, Pfizer Inc., Schering-Plough Corporation and 3M. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability And Reporting Limitations I-1
  • Disclaimers I-2
  • Data Interpretation & Reporting Level I-2
  • Quantitative Techniques & Analytics I-3
  • Product Definitions And Scope Of Study I-3
  • Inhaled Corticosteroids: I-3
  • Beta-2 Adrenoreceptor Agonists I-4
  • Combinations I-4
  • Anti- leukotrienes I-4
  • Others I-4
  • Antihistamines I-4
  • Methylxanthines I-4
  • Mast Cell Stabilizers I-5
  • Monoclonal Antibodies I-5
  • Anticholinergics I-5

II. EXECUTIVE SUMMARY

1. Market Overview II-1

  • Current & Future Analysis II-1
  • Competitive Outlook II-1
  • Major Asthma Therapeutics by Class II-2
  • Facts about Asthma II-2

2. Trends & Issues II-3

  • Combination Drugs - Rule the World II-3
  • Novel Compounds To Pep Up Growth II-3
  • Rise in Pediatric Asthma To Keep Market Lucrative II-3
  • Toxic Nature of Asthma Drugs - A Serious Concern II-3
  • Life Threatening Drugs Under Regulatory Scan II-3

3. Product Overview II-4

  • Causes of Asthma II-4
  • Allergens II-4
  • Irritants II-4
  • Other Factors II-4
  • Classes in Asthma II-5
  • A. Mild Intermittent Asthma: II-5
  • B. Mild Persistent Asthma: II-5
  • C. Moderate Persistent Asthma: II-5
  • D. Severe Persistent Asthma: II-5
  • Asthma Treatments II-6
  • Combination Asthma Medications II-6
  • Over-the-Counter Asthma Medications II-6
  • Immunotherapy (Allergy shots) II-6
  • Alternative Therapies II-6
  • Asthma Therapeutics II-6
  • Corticosteroids II-7
  • Beta-2 Adrenoreceptor Agonists II-7
  • Mast Cell Stabilizers II-7
  • Monoclonal Antibodies II-7
  • Immune System: Natural Defenders II-7
  • Human Antibodies II-8
  • Polyclonal and Monoclonal Antibodies II-8
  • Leukotriene Inhibitors II-8
  • Methylxanthines: II-8
  • Combination Therapeutics: II-8
  • Off Label Therapeutics: II-8
  • Anticholinergics: II-8
  • Antihistamines: II-9
  • Asthma Therapeutics by Various Classes II-9

4. Product Launches/Innovations II-10

  • Future to Witness A Novel Therapeutic in Asthma Treatment II-10
  • Dr. Reddy's Releases Doxobid in India II-10
  • Novartis Files Approval for Xolair to Enter Japanese Market II-10
  • AstraZeneca Receives Approval for Symbicort II-10
  • GSK Alters Labels for Two Asthma Drugs II-10
  • DMI BioSciences Starts Evaluating DMI 8393 II-11
  • Inflazyme Begins Phase IIb Trial for IPL512,602 II-11
  • Neurim Develops A Neuroprotective Compound II-11
  • Xolair® Forays into UK II-11
  • Critical Therapeutics Rolls Out ZYFLO® II-11
  • Ivax Corp. Introduces Qvar EasiBreathe Inhaler II-12
  • Altana Rolls Out Respiratory Drug, Alvesco in the UK II-12
  • Sepracor Launches XOPENEX HFA II-12
  • Polyphor Commences Research for Protease Inhibitors II-12
  • Novartis Plans to Apply for A New Drug Approval II-12
  • Asmanex Twisthaler 220 mcg Receives US FDA Approval II-12
  • GroPep Completes Pre-Clinical Testing of T-Cell Peptide Drug II-13
  • Able Laboratories Obtains FDA Approval II-13
  • Acceleration Therapeutics' AT-101 Passes Laboratory Test II-13
  • Pharmaxis' New Tool to Assess Asthma Passes Clinical Trial II-13
  • Aventis Seeks FDA Approval Alvesco® II-13
  • Schering-Plough Releases Asmanex Twisthaler II-13
  • FDA Clears Xolair to Enter US Market II-14
  • Sepracor Completes Phase III Trial for XOPENEX II-14
  • Pfizer Conducts Phase II Clinical Studies II-14
  • Celera and Bayer Plans to End Collaboration II-14
  • Banyu and Kyorin Starts Distribution of Asthma Treatment II-14
  • GlaxoSmithKline Introduces Advair II-14
  • Novartis Gets FDA Approval for Foradil Aerolizer II-14

5. Recent Industry Activity II-15

  • Teva Purchases Ivax II-15
  • SkyePharma Strikes A Deal with KOSP II-15
  • Ranbaxy Inks an In-Licensing Agreement with Eurodrug II-15
  • Pfizer and Rigel Forms A Collaboration II-15
  • MAP and Elan Extends Agreement II-15
  • Glenmark Collaborates with Teijin Pharma II-16
  • Pfizer Acquires Meridica II-16
  • Bayer and Apax Forms A New Company II-16
  • KOSP Signs Multiple Agreements II-16
  • Novartis Pharma Inks A Licensing Agreement with Ivax II-17
  • LAB Intends to Purchase Seyvika II-17
  • ALTANA and Tanabe Signs A Pact II-17

6. Focus on Select Players II-18

  • Abbott Laboratories (US) II-18
  • ALTANA Pharma AG (Germany) II-18
  • AstraZeneca (UK) II-18
  • Boehringer Ingelheim (Germany) II-19
  • Genentech, Inc. (US) II-19
  • GlaxoSmithKline (UK) II-19
  • Merck & Co., Inc. (US) II-19
  • Novartis Pharma AG (Switzerland) II-19
  • Pfizer Inc. (US) II-20
  • Schering-Plough Corporation (US) II-20
  • Sepracor Inc. (US) II-20
  • The Sanofi-Aventis Group (US) II-21
  • 3M (US) II-21

7. Global Market Perspective II-22

  • Table 1: World Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-22
  • Table 2: World 10-Year Perspective for Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-22
  • Table 3: World Recent Past, Current and Future Analysis for Inhaled Corticosteroids by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-23
  • Table 4: World 10-Year Perspective for Inhaled Corticosteroids by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-23
  • Table 5: World Recent Past, Current and Future Analysis for Short Acting Beta Agonists by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-24
  • Table 6: World 10-Year Perspective for Short Acting Beta Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-24
  • Table 7: World Recent Past, Current and Future Analysis for Long Acting Beta Agonists by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-25
  • Table 8: World 10-Year Perspective for Long Acting Beta Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-25
  • Table 9: World Recent Past, Current and Future Analysis for Combinations by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-26
  • Table 10: World 10-Year Perspective for Combinations by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-26
  • Table 11: World Recent Past, Current and Future Analysis for Anti-Leukotrienes by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-27
  • Table 12: World 10-Year Perspective for Anti-Leukotrienes by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-27
  • Table 13: World Recent Past, Current and Future Analysis for Other Asthma Therapeutics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-28
  • Table 14: World 10-Year Perspective for Other Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-28

III. MARKET

1. The United States III-1

  • A. Market Analysis III-1
  • Current & Future Analysis III-1
  • Asthma Reflections in the US III-1
  • Competitive Scenario III-1
  • Table 15: Leading Anticholinergic Companies in the US (2006): Percentage Breakdown of Market Share for Boehringer Ingelheim, Dey Inc, Alpharma and Others (includes corresponding Graph/Chart) III-1
  • Product Launches/Innovations III-2
  • Strategic Developments III-4
  • Focus on Key Players III-5
  • 3M III-5
  • Abbott Laboratories III-5
  • Genentech, Inc. III-5
  • Merck & Co., Inc. III-6
  • Pfizer Inc. III-6
  • Schering-Plough Corporation III-6
  • Sepracor Inc. III-6
  • The Sanofi-Aventis Group III-7
  • B. Market Analytics III-8
  • Table 16: US Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-8
  • Table 17: US 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010(includes corresponding Graph/Chart) III-9

2. Canada III-10

  • A. Market Analysis III-10
  • Current & Future Analysis III-10
  • Product Launches/Innovations III-10
  • Strategic Development III-10
  • B. Market Analytics III-11
  • Table 18: Canadian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-11
  • Table 19: Canadian 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-12

3. Japan III-13

  • A. Market Analysis III-13
  • Current & Future Analysis III-13
  • Product Approvals/Launches III-13
  • Strategic Developments III-13
  • B. Market Analytics III-14
  • Table 20: Japanese Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets IndependentlyAnalyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-14
  • Table 21: Japanese 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-15

4. Europe III-16

  • Market Analysis III-16
  • Current & Future Analysis III-16
  • Table 22: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region - France, Germany, UK, Italy, Spain and Rest of Europe Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-16
  • Table 23: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-17
  • Table 24: European 10-Year Perspective for Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain and Rest of Europe for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-18
  • Table 25: European 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-19

4a. France III-20

  • Market Analysis III-20
  • Current & Future Analysis III-20
  • Table 26: French Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-20
  • Table 27: French 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-21

4b. Germany III-22

  • A. Market Analysis III-22
  • Current & Future Analysis III-22
  • Product Launches/Innovations III-22
  • Focus on Key Players III-22
  • ALTANA Pharma AG III-22
  • Boehringer Ingelheim III-22
  • B. Market Analytics III-23
  • Table 28: German Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-23
  • Table 29: German 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-24

4c. The United Kingdom III-25

  • A. Market Analysis III-25
  • Current & Future Analysis III-25
  • Product Launches/Innovations III-25
  • Strategic Developments III-26
  • Focus on Key Players III-26
  • AstraZeneca III-26
  • GlaxoSmithKline III-26
  • B. Market Analytics III-27
  • Table 30: UK Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-27
  • Table 31: UK 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-28

4d. Italy III-29

  • Market Analysis III-29
  • Current & Future Analysis III-29
  • Table 32: Italian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-29
  • Table 33: Italian 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-30

4e. Spain III-31

  • Market Analysis III-31
  • Current & Future Analysis III-31
  • Table 34: Spanish Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-31
  • Table 35: Spanish 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-32

4f. Rest of Europe III-33

  • A. Market Analysis III-33
  • Current & Future Analysis III-33
  • Product Approvals/Launches III-33
  • Strategic Development III-34
  • Focus on Select Player III-34
  • Novartis Pharma AG (Switzerland) III-34
  • B. Market Analytics III-35
  • Table 36: Rest of Europe Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-35
  • Table 37: Rest of Europe 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006and 2010 (includes corresponding Graph/Chart) III-36

5. Rest of World III-37

  • A. Market Analysis III-37
  • Current & Future Analysis III-37
  • Product Launches III-37
  • Strategic Developments III-37
  • B. Market Analytics III-38
  • Table 38: Rest of World Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists,Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-38
  • Table 39: Rest of World 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-39

IV. COMPETITION

  • 1. 3M Company (USA) IV-1
  • Table 40: First Quarter Sales Analysis: 2005-2006 (In US$ billion) IV-5
  • Table 41: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion) IV-5
  • Table 42: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-5
  • Table 43: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-5
  • Table 44: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-6
  • 2. Abbott Laboratories (USA) IV-21
  • 3. Able Laboratories, Inc. (USA) IV-30
  • 4. Adams Respiratory Therapeutics (USA) IV-31
  • Table 45: Annual Sales Analysis: 2004-2006 (In US$ million) IV-31
  • Table 46: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million) IV-32
  • Table 47: Annual Sales Analysis by Product: 2005-2006 (In US$ million) IV-32
  • Table 48: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-32
  • 5. Aerovance, Inc. (USA) IV-34
  • 6. Almirall Prodesfarma SA (Spain) IV-35
  • 7. Alpharma USPD, Inc. (USA) IV-37
  • 8. Altana Pharma AG (Germany) IV-38
  • Table 49: Annual Sales Analysis: 2004-2005 (In € billion) IV-39
  • Table 50: Annual Sales Analysis by Product Segment: 2004-2005 (In € billion) IV-39
  • Table 51: Annual Sales Analysis by Geographical Region: 2004-2005 (In € billion) IV-39
  • 9. Amgen, Inc. (USA) IV-41
  • Table 52: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-42
  • Table 53: Annual Sales Analysis: 2004-2005 (In US$ million) IV-42
  • Table 54: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-42
  • 10. Asthmatx, Inc. (USA) IV-45
  • 11. Astrazeneca PLC (UK) IV-46
  • Table 55: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ Million) IV-48
  • Table 56: Half Yearly Sales Analysis By Quarter: 2005-2006 (H1) (In US$ Million) IV-49
  • Table 57: Half Yearly Sales Analysis By Geographic Region: 2005-2006 (H1) (In US$ Million) IV-49
  • Table 58: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) IV-49
  • Table 59: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) IV-49
  • Astrazeneca Pharmaceuticals LP (USA) IV-59
  • 12. Biocon India Limited (India) IV-63
  • Table 60: Annual Sales Analysis: 2004-2005 (In INR million) IV-64
  • 13. Boehringer Ingelheim GmbH (Germany) IV-67
  • Boehringer Ingelheim Pharmaceuticals, Inc. (USA) IV-71
  • Boehringer Ingelheim Ltd. (Canada) IV-71
  • 14. Breckenridge Pharmaceutical, Inc. (USA) IV-73
  • 15. Cadila Pharmaceuticals Limited (India) IV-74
  • 16. Cipla Ltd. (India) IV-77
  • 17. Coley Pharmaceutical Group, Inc. (USA) IV-80
  • Table 61: Half-Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousands) IV-80
  • Table 62: Quarterly Sales Analysis: 2005-2004 (In Can$ thousands) IV-81
  • 18. Cosmobio Co., Ltd. (Japan) IV-82
  • 19. Critical Therapeutics, Inc. (USA) IV-84
  • Table 63: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-84
  • 20. deCODE Genetics (Iceland) IV-86
  • Table 64: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-87
  • Table 65: Annual Sales Analysis: 2004-2005 (In US$ million) IV-87
  • Table 66: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-87
  • Table 67: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-87
  • 21. DMI BioSciences, Inc. (USA) IV-89
  • 22. Dr. Reddy's Laboratories (India) IV-90
  • Table 68: First Quarter Sales Analysis: 2005-2006 (Q1) (In INR billion) IV-92
  • Table 69: Annual Sales Analysis: 2004-2005 (In INR billion) IV-92
  • Table 70: Annual Sales Analysis by Segment: 2004-2005 (In INR billion) IV-93
  • Table 71: Annual Sales Analysis by Geographic Region: 2004-2005 (In INR billion) IV-93
  • 23. Elan Corporation Plc (Ireland) IV-97
  • Table 72: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-98
  • Table 73: Annual Sales Analysis: 2004-2005 (In US$ million) IV-98
  • Table 74: Annual Sales Analysis By Segment: 2004-2005 (In US$ million) IV-98
  • Table 75: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ million) IV-99
  • 24. Epitomics, Inc. (USA) IV-101
  • 25. Eurodrug Laboratories Group (The Netherlands) IV-103
  • 26. Exim Pharm International (India) IV-104
  • 27. F. Hoffmann-La Roche Ltd. (Switzerland) IV-106
  • Table 76: First Quarter Sales Analysis: 2005-2006 (In CHF billion) IV-107
  • Table 77: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion) IV-107
  • Hoffmann-La Roche, Inc. (USA) IV-110
  • Genentech, Inc. (USA) IV-113
  • Table 78: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-115
  • Table 79: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) (Switzerland)) IV-115
  • 28. Forest Laboratories, Inc. (USA) IV-119
  • Table 80: First Quarter Sales Analysis: 2006-2007 (In US$ billion) IV-120
  • Table 81: Annual Sales Analysis: 2004-2006 (In US$ billion) IV-120
  • Table 82: Annual Sales Analysis by Product: 2005-2006 (In US$ billion) IV-120
  • Table 83: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ billion) IV-121
  • Table 84: Quarterly Sales Analysis: 2005-2006 (In US$ billion) IV-121
  • 29. Gilead Sciences (USA) IV-125
  • Table 85: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In USS$ million) IV-126
  • Table 86: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million) IV-126
  • Table 87: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-127
  • Table 88: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-127
  • 30. Glaxosmithkline PLC (UK) IV-132
  • Table 89: Half Yearly Sales Analysis: 2005-2006 (H1) (In ? million) IV-133
  • Table 90: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In ? million) IV-133
  • Table 91: Annual Sales Analysis by Segment: 2004-2005 (In ? million) IV-133
  • Glaxosmithkline (USA) IV-142
  • 31. Glenmark Pharmaceuticals Ltd. (India) IV-145
  • Glenmark Pharmaceuticals SA (Switzerland) IV-145
  • 32. GroPep Limited (Australia) IV-146
  • Table 92: Annual Sales Analysis by Business Segment: 2005-2006 (In A$ million) IV-148
  • 33. Indoco Remedies (India) IV-150
  • 34. Inflazyme Pharmaceuticals Limited (Canada) IV-153
  • 35. Janssen-Cilag GmbH (Austria) IV-155
  • 36. Kos Pharmaceuticals, Inc. (USA) IV-156
  • Table 93: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-157
  • Table 94: Annual Sales Analysis: 2004-2005 (In US$ million) IV-157
  • 37. Kyorin Pharmaceutical Co., Ltd. (Japan) IV-159
  • 38. Lab International, Inc. (Canada) IV-160
  • Table 95: Annual Sales Analysis by Business Segment: 2004-2005 (In Can$ million) IV-161
  • Table 96: Annual Sales Analysis by Geographic Region: 2004-2005 (In Can$ million) IV-161
  • 39. Lark Laboratories (India) IV-164
  • 40. MAP Pharmaceuticals, Inc. (USA) IV-166
  • 41. Mayne Pharma Pty, Ltd. (Australia) IV-167
  • Table 97: Annual Sales Analysis By Segment: 2004-2005 (In A$ Million) IV-167
  • Table 98: Annual Sales Analysis By Geographic Region: 2004-2005 (In A$ Million) IV-168
  • 42. MediciNova, Inc. (USA) IV-171
  • Table 99: Half-Yearly Sales Analysis: 2005-2006 (H1) (In US$ Thousand) IV-171
  • 43. Mercia Pharma, Inc. (USA) IV-175
  • 44. Merck KGaA (Germany) IV-176
  • Table 100: Annual Sales Analysis Segment: 2004-2005 (In € million) IV-178
  • Merck & Co., Inc. (USA) IV-182
  • Table 101: Half Yearly Sales Analysis By Quarter: 2005-2006 (H1) (In US$ million) IV-183
  • Table 102: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million) IV-183
  • Table 103: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-183
  • Table 104: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-184
  • Banyu Pharmaceutical Co., Ltd. (Japan) IV-186
  • Dey, L.P. (USA) IV-187
  • 45. Millennium Pharmaceuticals, Inc. (USA) IV-189
  • Table 105: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-189
  • Table 106: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-189
  • 46. MorphoSys AG (Germany) IV-192
  • Table 107: First Quarter Sales Analysis: 2005-2006 (Q1) (In € million) IV-192
  • 47. Neurim Pharmaceuticals (1991) Ltd. (Israel) IV-194
  • 48. Nicholas Piramal India Ltd. (India) IV-195
  • Table 108: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-196
  • 49. Novartis AG (Switzerland) IV-197
  • Table 109: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-200
  • Table 110: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-201
  • Table 111: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-201
  • Table 112: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-201
  • Novartis Pharma Switzerland AG (Switzerland) IV-209
  • Novartis Pharma GmbH (Germany) IV-210
  • Sandoz International GmbH (Germany) IV-210
  • 50. Oriel Therapeutics, Inc. (USA) IV-212
  • 51. Pfizer, Inc. (USA) IV-213
  • Table 113: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-215
  • Table 114: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion) IV-215
  • Table 115: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion) IV-216
  • Pfizer Consumer Healthcare Division (USA) IV-220
  • 52. Pharmaxis Ltd. (Australia) IV-224
  • 53. Polyphor Limited (Switzerland) IV-226
  • 54. Pure Pharma Limited (India) IV-228
  • 55. Ranbaxy Laboratories Ltd. (India) IV-229
  • 56. Rigel Pharmaceuticals, Inc. (USA) IV-243
  • Table 116: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-243
  • Table 117: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-244
  • 57. Sanofi-Aventis (France) IV-245
  • Table 118: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-246
  • Table 119: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million) IV-246
  • Table 120: Annual Sales Analysis: 2004-2005 (In € million) IV-246
  • Table 121: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-246
  • Table 122: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-247
  • Sanofi-Aventis (USA) IV-252
  • 58. Schering-Plough Corporation (USA) IV-254
  • Table 123: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-255
  • Table 124: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-256
  • Table 125: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-256
  • Table 126: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-256
  • AESCA Pharma GmbH (Austria) IV-260
  • 59. Sepracor, Inc. (USA) IV-261
  • Table 127: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-261
  • Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-262
  • 60. Shinpoong Pharmaceutical Co., Ltd. (South Korea) IV-265
  • 61. SkyePharma PLC (UK) IV-266
  • Table 129: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In ? million) IV-267
  • Table 130: Annual Sales Analysis by Segment: 2004-2005 (In ? million) IV-267
  • Table 131: Annual Sales Analysis by Geographic Region: 2004-2005 (In ? million) IV-268
  • 62. Sumit Laboratories (India) IV-271
  • 63. Surya Pharmaceutical Ltd. (India) IV-272
  • 64. Synairgen Research Limited (UK) IV-272
  • 65. Tanabe Seiyaku Co., Ltd. (Japan) IV-273
  • Table 132: First Quarter Sales Analysis: 2006-2007 (Q1) (In US$ million) IV-273
  • Table 133: First Quarter Sales Analysis by Business Segment: 2005-2006 (Q1) (In Yen million) IV-274
  • Table 134: Annual Sales Analysis: 2005-2006 (In US$ million) IV-274
  • Table 135: Annual Sales Analysis by Business Segment: 2004-2005 (In Yen million) IV-274
  • 66. TEVA Pharmaceutical Industries Ltd. (Israel) IV-277
  • Table 136: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-278
  • Table 137: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-278
  • IVAX Corporation (USA) IV-287
  • Table 138: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289
  • Table 139: Quarterly Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289
  • Table 140: Nine Months Sales Analysis by Product Category: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289
  • Table 141: Nine Months Sales Analysis by Geographical Region: 2004-2005 (Nine Months Ended, September) (In US$ billion)Limited (Israel)) IV-290
  • Ivax Laboratories, Inc. (USA) IV-295
  • 67. Trudell Medical International (Canada) IV-296
  • 68. UCB SA (Belgium) IV-297
  • Table 142: Annual Sales Analysis: 2004-2005 (In € million) IV-297
  • Table 143: Annual Sales Analysis By Business Segment: 2004-2005 (In € million) IV-297
  • 69. Zedawn Formulations (P) Ltd. (India) IV-300
  • 70. Zenyth Therapeutics Limited (Australia) IV-301
  • Table 144: Annual Sales Analysis: 2004-2005 (In A$ million) IV-301
Back to Top